Spots Global Cancer Trial Database for Safety Study on AdCD40L Gene Therapy for Bladder Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety Study on AdCD40L Gene Therapy for Bladder Cancer
Official Title: A Phase I/IIa Study of Dose-escalating Intravesical AdCD40L Instillation in Urinary Bladder Carcinoma
Study ID: NCT00891748
Conditions
Interventions
Study Description
Brief Summary: The study objective is to evaluate the feasibility of three instillations of immunostimulating gene therapy (AdCD40L) in patients with urinary bladder cancer. Tolerance, toxicity and immunological parameters will be evaluated during and post treatment.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Uppsala University Hospital, Uppsala, , Sweden
Contact Details
Name: Per-Uno Malmstrom, MD PhD
Affiliation: Uppsala University Hospital, Uppsala, Sweden
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
